Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 67Pancreatic Neoplasms 34Neoplasm Metastasis 22Neuroblastoma 21Neoplasms 16Colonic Neoplasms 15Stomach Neoplasms 13Rectal Neoplasms 13Sarcoma, Ewing 8Rhabdomyosarcoma 8Esophageal Squamous Cell Carcinoma 8Small Cell Lung Carcinoma 7Sarcoma 7Ovarian Neoplasms 6Lung Neoplasms 6Cholangiocarcinoma 6Esophageal Neoplasms 5Breast Neoplasms 5Adenocarcinoma Of Esophagus 5Medulloblastoma 4Gastrointestinal Neoplasms 4Endometrial Neoplasms 4Biliary Tract Neoplasms 4Adenocarcinoma 4Recurrence 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Osteosarcoma 3Glioma 3Glioblastoma 3Ganglioneuroblastoma 3

Interventions

trastuzumab deruxtecan 1toripalimab 1pertuzumab 1pembrolizumab 1fludarabine 1atezolizumab 1Trastuzumab 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cyclophosphamide 1Cetuximab 1Carboplatin 1Capecitabine 1Bronchoscopes 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Cancer × Irinotecan × 1 year × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡